Dr. Erin Muhlbradt is a contractor for the US National Cancer Institute’s Enterprise Vocabulary Services (NCI EVS) and is the NCI EVS and CDISC project lead for CDISC terminology development. Dr. Muhlbradt has over 10 years’ experience in the bioinformatics and pharmaceutical industries, with skills including terminology development, standards development, database and metadata repository development, and data modeling.
She manages a team at EVS that is responsible for the development, publication, and maintenance of CDISC controlled vocabularies in use by the pharmaceutical industry and mandated by the US Food and Drug Administration (FDA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Her duties include project management, biomedical and clinical subject matter expertise, terminology development, quarterly terminology publications, and management of the CDISC terminology change request mechanism. Previously, Erin was a doctoral candidate at Georgetown University in the Tumor Biology department and she performed her thesis work in prostate cancer cell signaling in laboratories at Georgetown University (Washington, DC) and Columbia University (New York, NY).
Erin holds a Bachelor of Science Degree (Honors) in Molecular and Cellular Biology from the University of Glasgow (Glasgow, Scotland) and a Doctoral Degree in Tumor Biology from Georgetown University (Washington, DC).
Erin leads, co-leads, or oversees 19 active CDISC controlled terminology teams. She is a co-lead of the SDS PGx subteam, a co-lead of the SDS Cell Phenotyping sub-team, a voting member of the CDISC Global Governance Group (GGG), and a terminology representative on many active therapeutic area standards development teams.